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Background: Corneal oedema is a common post-operative problem that delays or prevents visual recovery from ocular surgery. Honey is a supersaturated 
solution of sugars with an acidic pH, high osmolarity and low water content. These characteristics inhibit the growth of micro-organisms, reduce oedema and 
promote epithelialisation. This clinical cases series describes the use of a regulatory approved Leptospermum species honey ophthalmic product, in the 
management of post-operative corneal oedema and bullous keratopathy. 
Methods: A retrospective review of consecutive cases (n=18 patients, n=30 eyes) of corneal oedema persisting beyond one month post-operative following 
single or multiple ocular surgeries (phacoemulsification cataract surgery and additional procedures) treated with Optimel™ Antibacterial Manuka Eye Drops 
twice to three times daily as an adjunctive therapy to conventional topical management with corticosteroid, aqueous suppressants, hypertonic sodium chloride 
5%, eyelid hygiene and artificial tears. Visual acuity and central corneal thickness were measured before and at the conclusion of Optimel™ treatment. 
Results: A temporary reduction in corneal epithelial oedema lasting up to several hours was observed after the initial Optimel™ instillation and was 
associated with a reduction in central corneal thickness, resolution of epithelial microcysts, collapse of epithelial bullae, improved corneal clarity, improved 
visualisation of the intraocular structures and improved visual acuity. Additionally, with chronic use, reduction in punctate epitheliopathy, reduction in central 
corneal thickness and improvement in visual acuity were achieved. Temporary stinging after Optimel™ instillation was experienced. No adverse infectious or 
inflammatory events occurred during treatment with Optimel™. 
Conclusions:  Optimel™ was a safe and effective adjunctive therapeutic strategy in the management of persistent post-operative corneal oedema and 
warrants further investigation in clinical trials. 
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Honey has a long history in eye care and wound care.
1
 Honey is a supersaturated solution of sugars with an acidic pH, high osmolarity and low water content. 
These characteristics inhibit the growth of microorganisms, reduce oedema and promote epithelialisation.
1-3 
Honey from a variety of floral sources and 
geographic locations, and in a range of concentrations, has been reported as an effective adjunctive treatment in the chronic management of ocular surface 
diseases, including Sjogen’s and non-Sjogren’s aqueous deficient dry eye (ADDE)
4,5 
meibomian gland dysfunction (MGD),
4
 herpes zoster-related  
neurotrophic keratitis,
6 
contact lens-related bacterial keratitis
7
 and as an antimicrobial prophylaxis for ocular surgery.
8
 In animal models, unprocessed honey 
demonstrated equivalent efficacy to conventional antibiotic therapies in the management of Staphylococcus aureus and Pseudomonas aeruginosa 
conjunctivitis and keratitis.
9-11
 
 
Honey was used in the management of a series of cases of co neal epithelial oedema and bullous keratopathy unsuitable for corneal grafting.
12-13
 Application 
of a drop of a pure raw local honey produced an immediate, complete, temporary clearing of the epithelial oedema lasting approximately one hour. Collapse of 
corneal bullae, improved visual acuity, increased visualization of the anterior segment and improved fundus evaluation were achieved in some eyes in this 
series. 
 
Despite advances in surgical techniques, corneal oedema is one of the most common complications of cataract surgery.
14,15 
Most post-operative corneal 
oedema is transient and subsides within the first days or weeks after surgery.
15-17 
However, in some cases, corneal oedema can be protracted, and if sufficient 
endothelial cell loss occurs, irreversible pseudophakic bullous keratopathy results.
14
  Persistent corneal oedema or corneal decompensation following cataract 
surgery occurs in  approximately 0.5% of cases.
14
 In a high volume cataract surgery clinic, a case of persistent post-operative corneal oedema would be 
expected to be encountered every few months. Hence strategies to manage this corneal oedema, including novel strategies, should be evaluated and 
employed if deemed safe and efficacious. 
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In this manuscript we demonstrate the effects of standardized antibacterial Leptospermum species honey on post-operative corneal oedema and present a 
series of post-surgical cases in which standardized medically regulated antibacterial honey was used in the management of corneal oedema persisting 
beyond a month after surgery. Potential roles for the use of standardized antibacterial honey in the management of corneal oedema and contributing 
properties are discussed. 
 
Methods 
Participants 
This report describes an uncontrolled retrospective case series of 18 consecutive clinic patients of Vision Eye Institute (Brisbane, Australia) who manifested 
post-operative corneal oedema in one or both eyes persisting beyond one month post-operative following single or multiple ocular surgeries 
(phacoemulsification cataract surgery and additional procedures) and were treated with standardized medically regulated antibacterial honey. All participants 
received a detailed explanation of the procedures involved in this study and provided informed consent for their de-identified clinical data and anterior segment 
images to be used in this review.  
Co-existent corneal and ocular surface diagnoses in eyes included in this case series were made at the time of the initial pre-operative evaluation for cataract 
surgery, primarily based on slit lamp biomicroscopic examination and included: 
Fuchs’ endothelial dystrophy (FED): In early cases, FED was diagnosed by presence of central corneal guttata. In more advanced cases, additional diagnostic 
features included corneal stromal oedema, fine striae in Descemet's membrane and microcystic epithelial oedema.
18
 
ADDE: Diagnosed by a scant inferior tear meniscus and verified by a Schirmer test without anaesthetic (Color Bar™, Eagle Vision, USA) of < 7 mm in 5 
minutes.
19  
MGD: Diagnosed based on diffuse abnormalities of the meibomian glands including terminal duct obstruction; lid margin hyperaemia, thickening, irregularity 
and telangectasia; and/or qualitative and quantitative changes in meibomian gland secretion.
20 
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Punctate epitheliopathy: Ocular surface vital staining with sodium fluorescein 2% was graded using the Oxford Scale
.21
 Staining score ranges from 0-5 for 
each of 3 zones (nasal conjunctiva, temporal conjunctiva, cornea) and 0-15 for the total exposed interpalpebral conjunctiva and cornea. A reduction in the total 
staining score of more than one grade on a 15 point scale was considered clinically significant. 
Study treatment 
In this case series, post operative oedema was treated with Optimel™ Antibacterial Manuka Eye Drops (98% Leptospermum spp. Honey, Melcare Biomedical 
Pty Ltd, Australia), applied to the inferior conjunctival sac two to three times daily. Optimel is a standardized, non-preserved, multidose, antibacterial honey 
product approved external ocular use. Optimel is prepared to a rigorous set of systems and standards from a unique proprietary mix of honeys from the 
Australian and New Zealand Leptospermum species (commonly known as Manuka and Jelly Bush). These honeys are selected for their highest and most 
consistent level of antibacterial activity, including against antibiotic resistant strains such as methicillin resistant Staphylococcus aureus and Pseudomonas 
aeruginosa and other exceptional physicochemical properties such as a high phenolic and flavonoid content
22-25
 and immunomodulatory effects.
26-28
 Optimel 
was the first therapeutic honey regulated as a medical device for professional eye care in Europe (CE marked) and Australia (ARTG Identifier 199785). 
Current approved treatment indications are dry eye disease due to aqueous tear deficiency and meibomian gland dysfunction and corneal epithelial erosions. 
In some cases this case series, Optimel™ was used as an adjunctive therapy to conventional topical management with corticosteroid, aqueous suppressants, 
and hypertonic sodium chloride 5% ointment in the case management of persistent post operative oedema. Additionally, all participants with a diagnosis of 
ADDE and/or MGD were treated with eyelid hygiene and preservative-free artificial tear supplements. To be prescribed Optimel™ and included in this 
consecutive clinical case series, individuals must have met the following criteria: no hypersensitivities or allergies to honey, bee products and/or natural 
hydrocolloid gums; and no ocular injury or additional ocular surgery during Optimel™ treatment.  
Before prescribing Optimel™ an instillation trial was performed on the intended to treat eye/s.  One drop of Optimel™ was applied to the inferior conjunctival 
sac using a sterile cotton applicator and the patient instructed to close their eye/s for two minutes. It was expected that the topical ocular use of honey would 
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produce transient stinging and conjunctival inflammation.
1,3-7,12,13
 If protracted inflammation and/or stinging was experienced, the patient was excluded from 
further treatment with honey. If the honey was tolerated, and biomicroscopic evidence of corneal clearing was noted, the patient was prescribed Optimel™ 
additional to any existing treatments. Treatment with Optimel™ was commenced between December 2012 and December 2013 and continued as clinically 
required for a period of months. In some cases, treatment continued beyond conclusion of data collection in April 2014. Individuals who were non-adherent to 
prescribed post-operative treatment instructions (including prescribed use of Optimel™) were excluded from this case series.  
Individual case specifics, including gender, age, ocular surgical procedures, associated relevant ocular diagnoses, eye/s treated with Optimel™, duration of 
treatment and concurrent topical treatments are outlined in Table 1.  
Assessments 
This study involved descriptive and analytical components. Corneal oedema diagnosis was based on slit-lamp biomicroscopic examination findings and 
ultrasonic pachymetry. Corneal oedema was defined as an increase in the ultrasonically measured central corneal thickness (CCT) from pre-operative values 
with or without Descemet’s folds.
15,16
 
Post-operative recovery from persistent corneal oedema in Optimel™ treated eyes was assessed clinically by measuring visual acuity (Snellen and LogMAR 
VA) and ultrasound CCT (SP-100 Handy Pachymeter, Tomy, USA). Ultrasound pachymetry is the gold standard technique for pachymetry in healthy 
corneas
29,30  
and in Fuchs’ corneal dystrophy.
31
The Tomy instrument internally calibrates and takes repeated measurements. Three separate consecutive 
readings were obtained from the anesthetised cornea, with the probe manually placed as close to perpendicular as possible at the centre of the cornea after 
instillation of one drop of non-preserved oxybuprocaine 0.4%. All assessments were performed at least two hours after waking (to counter the effects of 
overnight oedema) in a stable internal environment at 23 degrees Celsius and 60% humidity.  
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The assessments of VA and CCT were performed prior to commencement of Optimel™ treatment and at the cessation of Optimel™ treatment. “After 
Optimel™” values were obtained at least two hours after Optimel™ insertion.Optimel™ treatment was discontinued if there was a resolution of oedema 
observed clinically with slit lamp biomicrosopy and CCT had returned to pre-operative values, or at the time of corneal grafting in Case 3. However, some 
patients elected to continue Optimel™ as part of a corneal and ocular surface management regime beyond resolution of post-operative corneal oedema. If 
Optimel™ treatment was continuing beyond the data collection period for this case review series, post-treatment values for VA and central CCT appearing in 
Table 1 and used in the data analysis were those obtained at the conclusion of the data collection period. 
Analyses 
Differences between LogMAR VA and CCT at baseline and after Optimel™ treatment were analysed using the paired t test to assess for intra-individual 
differences. In eyes treated unilaterally with Optimel™, the data for the treated eye was included in the analysis. In eyes treated bilaterally with Optimel™, 
data for the eye with the greatest CCT at baseline was included in the analysis. SPSS Statistical Software Version 22 was used for statistical calculations.  
Additional cases 
An additional two non-sequential cases of postoperative corneal oedema in eyes with pre-existing corneal disease treated adjunctively with another pure 
sterile medically regulated Leptospermum spp. Honey product (Antibacterial Medical Honey, Medihoney, Comvita) after lack of response to conventional 
topical therapeutic  treatments are included this report but not incorporated in the above case series analysis.  
Results 
Mean duration of Optimel™ treatment was 12 ± 5 (3-15) months. The majority of cases involved female patients (14/18). FED was pre-existent in 50% (15/30) 
of cases and 53.3% (16/30) had pre-existent ADDE with or without MGD and 44.4% (8/18) of cases had undergone multiple intraocular surgeries. Cataract 
surgery complications (prolonged surgery, posterior capsular rupture and anterior vitrectomy, anterior chamber IOL insertion, Descemet’s detachment, post-
operative IOP spike) were contributory to the persistent corneal oedema in 22.2% (4/18) cases.  
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A temporary reduction in corneal epithelial oedema, resolution of epithelial microcysts, improved corneal clarity, and better visualisation of the intraocular 
structures (Figures 1, 2 and 3) lasting 1-2 hours after the initial Optimel™ application was observed in the clinic and verified by reduced CCT. In Case 3 and 
Case 7 (Table 1) corneal bullae collapsed within 10 minutes of Optimel™ application. Additionally, with chronic twice to three times daily dosing a clinically 
significant reduction in punctate epitheliopathy was observed in 7/18 treated eyes (Table 1).  
Aside from the temporary stinging and redness on application, no adverse events occurred during treatment with Optimel™.  
The Before Optimel™ and After Optimel™ values for VA and CCT respectively are recorded in Tables 2 and 3. A significant overall improvement in VA 
(p<0.00001) and reduction in CCT (p=0.000025) were achieved for this Optimel™ treated case series cohort.  The mean LogMAR acuity was 0.7 ± 0.2 pre-
treatment and 0.4 ± 0.2 post-treatment. The mean CCT was 643 ± 76 microns pre-treatment and 584 ± 55 microns after treatment. Figure 4 illustrates the 
reduction in persistent postoperative corneal oedema with Optimel™dosed thrice daily over 3 months of treatment. 
In the two additional non-sequential corneal oedema cases treated adjunctively with Antibacterial Medical Honey™ following lack of response to conventional 
therapy with topical steroid for an acute corneal graft rejection  (Figure 5A) and lack of response to topical fluoroquinolone antibiotic, eyelid hygiene and 
preservative free lubricants for a case of  filamentary keratitis with  presumed infectious infiltrate  (Figure 6A),  improved corneal clarity and reduced 
inflammation were observed clinically within one week of commencing antibacterial honey treatment at  three times daily dosing (Figures 5B and 6B). 
 
Discussion 
 
This retrospective case series review provides preliminary evidence of the safety and efficacy of standardized, regulatory approved, Leptospermum spp. 
antibacterial honey in the management of post-operative corneal oedema. Medically regulated pure antibacterial honeys may have numerous practical 
advantages when used in corneal disease. These include a rapid clinical effect (Figures 1, 2 and 3), preservative-free, long shelf-life, unaffected by UV, 
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storage at room temperature, low relative cost and relative abundance.
1-13
 Pure, raw honey is non-toxic to the ocular surface, even with chronic use in a 
compromised ocular surface,
4,6,7
 and allergy to honey is rare.
1-3
 High efficacy antibacterial Leptospermum spp. honeys can be used synergistically with 
antibiotic
32
 and immunomodulatory
33
 therapies. Leptospermum spp. honeys can be used concurrently with topical antimicrobial, anti-glaucoma and anti-
inflammatory therapies.
4,6-8
  
  
Antibacterial honey may have several potential roles in the management of acute and chronic corneal oedema. These roles include hyperosmotic (Figures 1- 
4), immunomodulatory (Figure 5) and antimicrobial effects (Figure 6). Pure raw honey is a powerful hyperosmotic agent due to its high sugar content and low 
water content. The osmotic pressure of honey exceeds 2000milliosmols/kg and it can rapidly (within 10-15 minutes) draw fluid from the corneal epithelium and 
anterior stroma, to temporarily clear an oedematous  anterior cornea, resolve microcystic oedema and collapse epithelial bullae.
12,13
 In this case series, we 
observed improved VA, reduced corneal pachymetry, and increased visualization of the posterior cornea, anterior segment and fundus detail in oedematous 
corneas within 30 minutes of Optimel™ of instillation (Figures 1-  3). Optimel™ contains a small amount of a naturally occurring food gum to increase viscosity 
and prolong retention time on the ocular surface which may enable a protracted hyperosmotic effect for up to several hours.  
 
Some honeys, including some Leptospermum species honeys, have broad spectrum antimicrobial properties and show efficacy against antibiotic resistant 
strains 
1-4,9,22-25,34-36
 and hence are an ideal prophylaxis before and after intraocular surgery
8
 in eyes at increased risk of post-operative infection, including 
those eyes with dry eye disease and/or bullous keratopathy in this case series. The acidic pH (mean 4.4), high osmolarity and low water content of pure raw 
honeys inhibit bacterial colonization. Additional antimicrobial activity is generated on dilution of honey by the activation of bee-derived glucose oxidase to 
produce low levels of hydrogen peroxide.
36
 On the ocular surface this dilution is likely to occur with reflex tearing produced in response to the stinging from the 
low pH of the honey. Methylglyoxal  and cationic antimicrobial peptide bee defensin-1 also act as antibacterial substances in some honeys, including some 
Leptospermum species honeys.
36-38
 The authors have previously assessed the effect of pure medical grade Leptospermum spp. honey (Antibacterial Medical 
Honey, Medihoney, Comvita) on the ocular flora in patients with a compromised ocular surface due to ADDE and/or MGD.
4 
Honey applied thrice daily to the 
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inferior conjunctival sac significantly reduced total eyelid margin and conjunctival sac bacterial colony forming units from baseline at month 1 and 3.
4
 Cernak 
and co-workers
8
 determined that a 25% monofloral Abies spp. honeydew honey used at five times daily dosing for seven days before cataract or vitrectomy 
surgery and five days after surgery was not significantly different to 0.3% topical oﬂoxacin used at the same dosing schedule in reducing bacterial isolates in 
the conjunctival sac. Unprocessed, multifloral honey used at four times daily dosing was as effective as the appropriate topical antibiotics in eradicating E. coli, 
Proteus sp., S. aureus, Klebsiella sp., and P. aeruginosa, and resolving conjunctival redness, swelling and discharge in a rat model of bacterial conjunctivitis.
9
 
Regulated medical grade honeys such as Optimel™ are sterilized by gamma irradiation to destroy spore-forming organisms that may be present in the honey 
without loss of antibacterial activity.
39
  
 
Evidence for the corneal anti-inflammatory effects of honey from animal models and in vitro investigations suggests that some honeys, including some 
Leptospermum species honeys, have immunomodulatory activity that may be additional to the aforementioned antimicrobial effects.
26-28
 A  rabbit corneal alkali 
burn model treated topically and orally with multifloral Tualang honey demonstrated reduced conjunctival hyperaemia ,corneal oedema and neutrophil 
infiltration that was not significantly different to conventional corneal burn management with Prednisolone acetate 1% and Ciprofloxacin 0.3% and oral 
ascorbic acid.
40
 In a rat model of corneal abrasion and Pseudomonas aeruginosa toxin immune mediated keratitis
41
, topical application of pure raw multifloral 
soybean/wildflower honey to injured corneas resulted in faster epithelialization and decreased corneal expression of vascular endothelial growth factor, 
transforming growth factor beta, interferon gamma, interleukin 12, chemokines and tumour necrosis factor alpha compared with untreated corneas. 
Application of honey to intact control corneas did not elicit any such anti-inflammatory response.
41
 Postoperative inflammation has been identified as a cause 
of persistent post-operative corneal oedema following cataract surgery.
14,42,43
 Persistent corneal inflammation and vascularisation increase the risk of corneal 
graft rejection in eyes undergoing grafting for post operative corneal decompensation.
43
  Hence these immune modulatory properties of honey may be of 
benefit in the management of post graft eyes in the prevention and management of corneal graft rejection as illustrated in Figure 5. 
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Raw honeys can reduce corneal epitheliopathy,
4,5,
 and promote corneal epithelialisation when used in the management of infectious and inflammatory 
keratitis.
6,7,40,41
 It is hypothesized that the antimicrobial, immunomodulatory and hyperosmotic properties of the honey are responsible for promoting 
epithelialization and improved ocular surface epithelial integrity, but the exact mechanisms of action are still to be determined.
2
 The improved epithelial 
integrity observed in 7/18 subjects with chronic Leptospermum spp. Honey use observed  in this case series (Table 1)  has multiple potential benefits for post 
surgical patients: reduced risk of infection (Figure 6), improved vision, increased refractive stability and reduced symptoms of ocular irritation. However, 
temporary stinging and redness with honey application occurs in all patients, with the exception of those with neurotrophic corneas
6
, which may limit uniform 
acceptance and ongoing patient commitment to treatment.
4
  
 
The authors acknowledge that the beneficial effects of antibacterial honey in corneal oedema management are limited to the epithelium and stroma.  Whilst 
pure raw irradiated honey may have beneficial hyperosmotic, antimicrobial and anti-inflammatory effects in cases of persistent bullous keratopathy, it will not 
cure the condition.
12,13
 Endothelial loss and dysfunction is the main cause of severe and persistent post-operative corneal oedema, particularly in those cases 
associated with Fuchs’ endothelial dystrophy.
16,18,42-44
 Honey cannot penetrate beyond the intact epithelium so its benefits within the stroma and anterior 
chamber are limited unless the epithelium is significantly compromised or removed.
13,41
 Hence in Case 3 of this series, involving a patient with significant 
corneal oedema and bullous keratopathy persisting at 4 months post cataract surgery, with only modest improvement in acuity despite intensive medical 
treatment with topical steroid, aqueous suppressants, hypertonic saline and Optimel™, the patient was referred for a corneal graft procedure.  
 
Honey was used adjunctive to the conventional management of persistent post-surgical corneal oedema.  Initial treatment of post operative oedema involves 
addressing the surgically and medically treatable causes such as inflammation, infection, elevated IOP, IOL misalignment, retained lens fragments and 
Descemet’s membrane detachment.
14
 Topical penetrating corticosteroids, such as prednisolone acetate 1%, may be required to treat persistent anterior 
chamber inflammation (Table 1, Cases 3,5,7, 18). Topical aqueous suppressants, such as the alpha-adrenergic agonist, brimonidine 0.2% (Alphagan) may be 
required to control elevated IOP (Table 1, Cases 3,5,11).Topical broad spectrum antibiotic prophylaxis and close monitoring are recommended in cases of 
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epithelial breakdown associated with bullous keratopathy due to an increased risk of microbial keratitis. Hypertonic agents such as 5% hypertonic sodium (e.g. 
Muro 128, Bausch and Lomb, USA) (Table 1 Cases 2,3,5,7,9,11) have may have a marginal transient benefit in reducing corneal oedema due to a relatively 
weak osmotic effect,
12-14, 42 
Topical compounded anhydrous glycerine can have a rapid (within 2 minutes), but transient, hyperosmotic effect on corneal 
oedema. However, topical glycerine is unsuitable for chronic use due to the absence of an approved topical glycerine product and considerable stinging, 
injection and photophobia on instillation.
42
  
This case series has several limitations related to being an uncontrolled retrospective review. The proportion of the clinical improvements in corneal oedema, 
VA and CCT attributable to Optimel™ are difficult to determine in each of the cases outlined. In some cases Optimel™ was additive to other conventional 
treatments for corneal oedema, and the passage of time from surgery in itself can be a significant factor in the resolution of post-surgical corneal oedema.
15-17 
The limitations of ultrasound pachymetry used to measure CCT as an efficacy parameter also warrant consideration. This contact procedure requires topical 
anaesthesia, and the probe can indent the cornea and disrupt the epithelium, which may result in erroneous readings
29,45
 This source of measurement error 
may potentially be greater in an oedematous cornea.
45
 Ultrasound pachymetry did not permit examination of individual layers of the cornea for changes in 
thickness with Optimel™ treatment. Pachymetry was only measured in the centre of the cornea and this measurement may underestimate of the thickest area 
of the cornea when more oedema is located elsewhere on the cornea,for example in Figures 1 and 4. Non-contact methods such as optical coherence 
tomography (OCT) can evaluate the epithelial, stromal and total corneal thickness across the entire cornea (Figure 4).
29.30
 A comparison of the repeatability 
and reproducibility of the CTT measured using the spectral domain  RTVue OCT (Optovue), time domain Visante OCT (Zeiss) and slit lamp mounted 
ultrasound pachymeter found that the RTVue had a smaller repeatability coefficient than the Visante and ultrasound pachymeter (4.7, 8.3, and 7.7 µm, 
respectively) but intersession reproducibility of ultrasound was superior to the RTVue and Visante (7.7, 11.8 and 8.8 µm) 
29
 A prospective randomised 
controlled clinical trial, using ultrasound pachmetry for CCT and a repeatable non-contact instrument combining topographic pachymetry and high resolution 
layer by layer corneal imaging such as the Optovue OCT (Figure 4), would be required to determine the component of the recovery of corneal oedema 
attributable to Optimel™ versus the impact of other treatments (steroids, aqueous suppressants,hypertonic saline) and the effect of time from surgery on 
corneal oedema resolution. 
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Despite the foregoing limitations, our initial clinical findings suggest that antibacterial honey appears to have some favourable properties and outcomes for 
post-surgical corneal oedema management. Further assessment of the roles, mechanisms and clinical benefits of antibacterial honey in the management of 
persistent post operative oedema is therefore indicated in the form of a controlled prospective randomised clinical trial. 
Furthermore, evaluation of the potential uses of antibacterial honeys in the management of acute and chronic corneal oedema associated with non-surgically 
induced conditions such as endothelial dystrophies, primary and secondary acute angle closure, corneal trauma, hydrops in keratoconus, interstitial keratitis, 
contact lens hypoxia, filamentary keratitis and medicamentosa is warranted. 
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Table 1 Cases of Persistent Post Operative Corneal Oedema following phacoemsulsification treated with standardised Leptospermum species 
honey: Associated Diagnoses, Optimel™ Dose and Duration, Additional treatments and Clinical Outcomes   
 
Case Gender  
Age 
(years) 
Associated ocular conditions Optimel™
Dose  
Optimel™
Months  
Concurrent Treatments Clinical Outcome with Optimel™. 
RE LE   
1.  F 74  FED  FED + DSEK  t.i.d. OU 15  ↑ VA LE; ↓ CCT LE; ↓ Epitheliopathy LE 
2.  F63  FED+MGD+ADDE  FED +MGD +ADDE t.i.d. OU 15 Muro OU    ↑ VA OU, ↓ CCT OU; ↓ Epitheliopathy OU 
3.  F75  FED FED t.i.d. LE 4 PF+ Alphagan LE ↑ VA LE; ↓ CCT LE.  
4.  M 87  FED  FED  t.i.d. OU 15  ↑ VA OU; ↓ CCT  
5.  F80  Vitrectomy   t.i.d.RE    PF+Alphagan+Muro RE ↑ VA RE; ↓ CCT RE 
6. F67  FED+ ADDE  FED+ADDE t.i.d. OU 15  ↑ VA OU; ↓ CCT OU; ↓ Epitheliopathy LE  
7.  F84  AK  t.i.d.RE   3 PF+ Muro RE  ↑ VA RE; ↓ CCT RE  
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8. F72  FED+ RD FED  t.i.d. OU 13  ↑ VA OU; ↓ CCT OU  
9. F75  FED+ ADDE  FED+ ADDE  t.i.d. OU  14 Muro OU ↑ VA OU; ↓ CCT OUOU  
10. F65  FED+ADDE  FED+ADDE  t.i.d. OU 15  ↑ VA OU;↓ CCT LE;↓ 
 
11. F62  Trab+ ADDE+MGD ADDE+ MGD  t.i.d. OU 15 Alphagan RE+Muro OU ↑ VA RE; ↓ CCT RE;  
12. F73  FED  FED  t.i.d. LE 15  ↑ VA OU; ↓ CCT OU 
13. F59  ADDE ADDE  t.i.d. OU 15  ↑ VA LE; ↓ CCT LE 
14. F74  MGD+ADDE MGD+ADDE+ACIOL+ trab t.i.d. OU 15  ↑ VA LE; ↓ CCT LE; ↓ Epitheliopathy LE 
15. F 61  Vitrectomy+ ADDE Vitrectomy+ ADDE  t.i.d. OU 6  ↑ VA OU, ↓ CCT OU; ↓ Epitheliopathy OU 
16. M80   Vitrectomy+ AC IOL+ADDE t.i.d. LE 14  ↑ VA LE; ↓ CCT LE ↓ Epitheliopathy LE 
17. M 73  MGD+ ADDE  MGD+ ADDE  b.i.d OU 15  ↑ VA OU; ↓ CCT OU↓ Epitheliopathy OU  
18. M 76   Descemet’s detachment  b.i.d LE 4 PF LE ↑ VA LE↓ CCT LE  
Table 1 Legend :  ↑ VA = improved Visual Acuity with Optimel™; ↓ CCT = reduced ultrasound central corneal thickness with Optimel™; ↓ Epitheliopathy = 
reduction in ocular surface punctuate epitheliopathy with Optimel™;AC IOL = anterior chamber IOL; ADDE = aqueous deficient dry eye; Alphagan = topical 
aqueous suppressant Brimonidine 2% (Allergan, USA) used twice daily for one month; AK=astigmatic keratotomy; b.i.d. = one drop instilled in the eye two 
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times per day; DSEK = Descemet’s stripping endothelial keratoplasty; F= female; FED = Fuchs’ corneal endothelial dystrophy; Optimel™ = Optimel™ 
Antibacterial Manuka Eye Drops (98% Leptospermum spp. honey ,Melcare Biomedical, Australia); LE = left eye; M=male,  MGD = meibomian gland 
dysfunction; Muro= Muro128 hypertonic sodium chloride 5% ointment (Bausch and Lomb, USA) applied to the eye at bedtime; OU = both eyes; PF = topical 
steroid Prednisolone acetate 1% (Allergan, USA) instilled twice daily for one month; RE = right eye.  
 
Table 2. Visual Acuity (VA) Before and After treatment with Optimel™ in Cases of Persistent Corneal Oedema Cases after Cataract Surgery 
Case  Eye VA Before 
Optimel™  
VA After 
Optimel™  
1. RE 6/9 6/9 
 LE 6/38 6/24 
2. RE 6/12 6/9 
 LE 6/15 6/7.5 
3. LE 6/60 6/38 
4. RE  6/12 6/9 
 LE 6/30 6/24 
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5. RE  6/60 6/12 
6. RE 6/15 6/12 
 LE 6/ 12 6/9 
7. RE 6/30  6/15 
8 RE 6/24 6/12 
 LE 6/15 6/9 
9 RE 6/15 6/12 
 LE 6/18 6/15 
10. RE 6/12 6/9 
 LE 6/18 6/12 
11. RE 6/15 6/12 
 LE 6/9 6/9 
12. LE 6/24 6/15 
13. RE 6/9 6/9 
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 LE 6/19 6/9 
14. RE 6/7.5 6/7.5 
 LE 6/24 6/12 
15. RE 6/12 6/7.5 
 LE 6/12 6/7.5 
16. LE 6/24 6/9 
17. RE 6/12 6/9 
 LE 6/48 6/24 
18. RE 6/36 6/9 
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Table3. Central corneal thickness (CCT) Before and After treatment with Optimel™ in Cases of Persistent Corneal Oedema Cases following 
Cataract Surgery 
 
Case  
 
 
Eye CCT Before 
Optimel™  
  
CCTAfter 
Optimel™  
 
1. RE 635 
 
630 
 LE 682 661 
2. RE 616 567 
 LE 637 576 
3. LE 790 734 
4. RE 601 579 
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 LE 624 594 
5. RE 778 624 
6. RE 649 613 
 LE 653 601 
7. RE 675 578 
8 RE 660 627 
 LE 641 607 
9 RE 609 573 
 LE 653 653 
10. RE 555 557 
 LE 595 540 
11. RE 561 557 
 LE 545 530 
12. LE 585 530 
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13. RE 574 570 
 LE 595 557 
14. RE 523 527 
 LE 569 530 
15. RE 533 500 
 LE 545 512 
16. LE 563 571 
17. RE 592 558 
 LE 560 520 
18. RE 692 578 
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Figure Captions 
Figure 1. Post-operative corneal oedema in the left eye of a 64-year-old male at one week post-operative phacoemulsification and posterior chamber IOL 
insertion for a mature left cataract, before (Figure 1A) and 15 minutes after (Figure 1B) Optimel™ was applied the cornea. VA improved temporarily from 6/48 
to 6/24 following Optimel™  application facilitating improved biomicroscopic examination of the posterior segment.  
Figure 2. Microcystic corneal epithelial oedema at one day post-operative cataract surgery associated with acute IOP elevation of 48mmHg, before (Figure 
2A) and 30 minutes after (Figure 2B) Optimel™  applied to the cornea. VA improved temporarily from 6/60 to 6/38 with resolution of the oedema facilitating 
improved biomicroscopic examination of the anterior segment.  
Figure 3. Corneal clearing following application of Optimel™  to the conjunctival sac of a patient (Case 5 Table 1) with persistent post-operative corneal 
oedema at one month following cataract surgery complicated by posterior capsular rupture and elevated IOP (Figure 3A). Progressive corneal clearing 
occurred to 30 minutes (Figure 3B) enabling greater visualization of anterior segment for an hour.  
Figure 4. Corneal pachymetry maps (iVue, Optovue, USA) for Case 5 (Table 1) featured in Figure 3, before Optimel™ (Figure 4A) and three months after 
Optimel™ (Figure 4B) was commenced at three times daily dosing. CCT reduced significantly and VA improved from 6/60 to 6/12.  
Figure 5. Corneal oedema associated with a corneal graft rejection episode initially managed with Prednefrin Forte instilled every two hours for two weeks 
(Figure 5A). One week after commencing topical application of pure Leptospermum spp. Honey (Antibacterial Medical Honey, Medihoney, Comvita) three 
times daily, in addition to the topical steroid regime, significant corneal clearing was noted (Figure 5B). 
Figure 6. Corneal oedema and filamentary keratitis associated with presumed a microbial keratitis in a post-cataract surgery patient with Sjogren’s syndrome 
using hourly topical fluoroquinolone (Ofloxacin) for 4 days without significant clinical improvement (Figures 6A and 6B). At one week after pure Leptospermum 
spp. Honey (Antibacterial Medical Honey, Medihoney, Comvita) was commenced at four times daily dosing additive to the Ofloxacin, the oedema had resolved 
and the defect had epithelialized (Figure 6C).  
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Figure 1. Post-operative corneal oedema in the left eye of a 64-year-old male at one week post-operative 
phacoemulsification and posterior chamber IOL insertion for a mature left cataract, before (Figure 1A) and 
15 minutes after (Figure 1B) Optimel™ was applied the cornea. VA improved temporarily from 6/48 to 6/24 
following Optimel™  application.  
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Figure 2. Microcystic corneal epithelial oedema at one day post-operative cataract surgery associated with 
acute IOP elevation of 48mmHg, before (Figure 2A) and 30 minutes after (Figure 2B) Optimel™  applied to 
the cornea. VA improved temporarily from 6/60 to 6/38 with resolution of the oedema facilitating improved 
biomicroscopic examination of the anterior segment.  
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Figure 3. Corneal clearing following application of Optimel™  to the conjunctival sac of a patient with 
persistent post-operative corneal oedema at one month following cataract surgery complicated by posterior 
capsular rupture and elevated IOP (Figure 3A). Progressive corneal clearing occurred at 15 minutes (Figure 
3B) and 30 minutes (Figure 3C) enabling greater visualization of anterior segment. Refer to Table 1 Case 5 
for further case details.  
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Figure 4. Corneal pachymetry maps (iVue, Optovue, USA) for the patient featured in Figure 3, showing 
progressive reduction in CCT from baseline before (Figure 4A) and 30 minutes after (Figure 4B) 
Optimel™  applied to the cornea. Three months after Optimel™ commenced at three times daily dosing CCT 
has reduced significantly (Figure 4C) and VA has improved from 6/60 to 6/12. Refer to Table 1 Case 5 for 
further case details.  
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Figure 5. Corneal oedema associated with acute corneal graft rejection initially managed with Prednefrin 
Forte instilled every two hours for two weeks (Figure 5A). One week after commencing topical application of 
antibacterial Manuka honey three times daily, in addition to the topical steroid regime, significant corneal 
clearing was noted (Figure 5B).  
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Figure 6. Corneal oedema and filamentary keratitis associated with presumed a microbial keratitis in a post-
cataract surgery patient with Sjogren’s syndrome using hourly topical fluoroquinolone (Ofloxacin) for 4 days 
without significant clinical improvement (Figures 6A and 6B). At one week after antibacterial Manuka honey 
was commenced at four times daily dosing additive to the Ofloxacin, the oedema had resolved and the 
defect had epithelialized (Figure 6C).  
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